8-KEarnings & ResultsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 28, 2008)

Filed February 28, 2008For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 28, 2008, to report its financial and operating results for the fourth quarter and full year ended December 31, 2007. The primary purpose of this filing is to provide investors with an update on the company's performance, as detailed in a press release issued on February 27, 2008. While the 8-K itself does not contain the detailed financial figures, it serves as the official notification that the company has released its earnings. Investors should refer to the attached Exhibit 99.1, the press release dated February 27, 2008, for specific information regarding revenue, profitability, research and development updates, and any other material operating or financial developments during the period. This filing is crucial for understanding Regeneron's financial health and operational progress as of the end of 2007.

Key Highlights

  • 1Regeneron Pharmaceuticals announced its Q4 and full-year 2007 financial and operating results on February 27, 2008.
  • 2The company filed an 8-K on February 28, 2008, to report these results.
  • 3The press release detailing the results is furnished as Exhibit 99.1 to the 8-K.
  • 4Investors can find specific financial and operational performance data within the February 27, 2008 press release.
  • 5This filing marks the official disclosure of the company's year-end 2007 financial status.
  • 6The report covers the period ending December 31, 2007.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report Regeneron Pharmaceuticals' financial and operating results for the fourth quarter and the full fiscal year ended December 31, 2007, as announced in their press release on February 27, 2008.

The detailed financial results are contained within the press release dated February 27, 2008, which is attached as Exhibit 99.1 to this 8-K filing.

Investors should look for key financial metrics such as revenue, net income/loss, earnings per share, cash flow, as well as updates on clinical trial progress, pipeline development, and any strategic initiatives or significant business developments from the fourth quarter and full year 2007.

This filing is the official SEC reporting mechanism for the financial results that were previously announced in a press release on February 27, 2008. It serves to make that information a matter of public record with the SEC.